News Releases

Home / Investor Relations

 

News Releases

Date Title and Summary
Toggle Summary Tyme, Inc. to Present at the Stifel 2018 Healthcare Conference on November 13th
NEW YORK , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME ), a clinical stage biotechnology company developing cancer therapeutics for pancreatic, prostate and sarcoma tumors, today announced that it will be featured as a presenting company at the Stifel 2018 Healthcare
Toggle Summary Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019
SM-88 to be included in pivotal Precision Promise pancreatic cancer trial led by Pancreatic Cancer Action Network (PanCAN) expected to commence in the first half of 2019   Interim data for SM-88 from Phase II pancreatic cancer trial expected in January 2019   Tyme continues to build out management
Toggle Summary Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
NEW YORK , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc , (Nasdaq: TYME ), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced the appointment of former Kite Pharma and Celgene executive, Michele Korfin as the Company’s
Toggle Summary Tyme’s SM-88 to be included in Pancreatic Cancer Action Network’s (PanCAN’s) Novel “Precision Promise(SM)” Adaptive Phase II/III Pancreatic Cancer Trial Platform
Innovative trial design intended to accelerate development of pancreatic cancer therapies Potential pivotal pathway for SM-88 monotherapy in the second-line pancreatic cancer setting Also planning to test SM-88 in combination with standard-of-care treatments NEW YORK , Oct.
Toggle Summary Tyme Technologies, Inc. and the Joseph Ahmed Foundation Announce Planned Trial for SM-88 in Ewing’s Sarcoma
Recognized sarcoma thought leader, Dr. Sant P. Chawla , will conduct the investigator-initiated Phase II study The Joseph Ahmed Foundation (“JAF”) will provide funding and patient support for the study while Tyme will provide study drug and certain administrative services The study is expected to
Toggle Summary Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors
Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors James Biehl appointed as Chief Legal Officer of Tyme ; to step down from the board of directors NEW YORK , Sept. 18, 2018 (GLOBE NEWSWIRE) --   Tyme Technologies, Inc.
Toggle Summary Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer
NEW YORK , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion of the Company’s Phase II trial in metastatic pancreatic
Toggle Summary Tyme Technologies, Inc. to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
NEW YORK , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will be featured as a presenting company at the Rodman & Renshaw 20th Annual Global Investment Conference
Toggle Summary Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019
NEW YORK , July 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal quarter ended June 30, 2018 .
Toggle Summary Tyme Technologies, Inc. Set to Join Russell 3000® Index
NEW YORK , June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set to join the Russell 3000 ®  Index at the conclusion of the Russell U.S.